US Patent 7,888,342: Milnacipran Fibromyalgia Patent Scope, Expiration, and Generic Entry Risk

US Patent 7,888,342 protects specific methods of using milnacipran to treat fibromyalgia. Its claims do not cover milnacipran as a chemical compound, a broad antidepressant indication, or every milnacipran formulation. The core protection is a treatment regimen using milnacipran, generally at 100 mg per day or 200 mg per day, including the Savella dosing schedules of 50 mg twice daily and 100 mg twice daily.

The patent is a method-of-use patent. Its principal commercial value was tied to the FDA-approved fibromyalgia indication for Savella, not to the underlying active pharmaceutical ingredient. Based on the patent’s priority history and the statutory patent term, the enforceable term has ended or is at the end of its nominal term, subject to confirmation from the USPTO maintenance and term-adjustment records.

What does US Patent 7,888,342 cover?

US Patent 7,888,342 covers treating fibromyalgia by administering milnacipran or a pharmaceutically acceptable salt of milnacipran to a patient in need of treatment.

The claims contain four operative limitations:

The disease must be fibromyalgia.
The active ingredient must be milnacipran or a pharmaceutically acceptable salt.
The administration must use an effective amount, or specified daily dosages.
The method excludes administration of phenylalanine, tyrosine, and tryptophan.

The patent does not claim a new milnacipran molecule. It claims the use of an existing compound for a specific disease and specified dosing regimens.

Claim structure

Claim	Main limitation	Commercial significance
1	Treating fibromyalgia with milnacipran or a salt	Broadest independent treatment claim
2	Treating fibromyalgia with about 100 mg daily	Covers the standard target daily dose
3	Claim 2, with tablet dosage form	Protects tablet administration under claim 2
4	Claim 2, with divided daily dosing	Covers split dosing
5	Claim 4, with 50 mg twice daily	Directly tracks the standard Savella regimen
6	Treating fibromyalgia with about 200 mg daily	Covers the maximum labeled daily dose
7	Claim 6, with tablet dosage form	Tablet-specific 200 mg regimen
8	Claim 6, with divided daily dosing	Covers split dosing at 200 mg daily
9	Claim 8, with 100 mg twice daily	Directly tracks the 200 mg/day regimen
10	Claim 9, with two 50 mg tablets morning and evening	Detailed tablet administration schedule

Claims 1, 2, and 6 are the principal independent claims. Claims 3 through 5 and 7 through 10 are narrower dependent claims.

How broad is the scope of claim 1?

Claim 1 is broad within the fibromyalgia indication but narrow outside it. It requires administering milnacipran or a pharmaceutically acceptable salt to a fibromyalgia patient. It does not require a tablet, a particular strength, a specific dosing frequency, or a particular salt.

A potentially infringing product or treatment would generally need to satisfy each limitation:

the patient has fibromyalgia;
milnacipran or its salt is administered;
the amount is effective; and
the treatment does not also include the excluded amino acids in a manner that defeats the claim.

The term “consisting essentially of” narrows the claim relative to “comprising,” but it does not necessarily exclude every excipient, co-medication, or clinical intervention. The legal effect generally turns on whether an added component materially changes the basic and novel characteristics of the claimed method. In this patent, the central method is the use of milnacipran for fibromyalgia treatment.

The phenylalanine, tyrosine, and tryptophan proviso is unusual in commercial terms. It appears designed to distinguish prior disclosure involving amino-acid supplementation or related treatment approaches. It is unlikely to create a practical barrier for ordinary milnacipran monotherapy, because routine treatment with milnacipran would not normally include those substances as required components.

What dosing regimens are protected?

The patent specifically covers two daily dose levels:

about 100 mg per day; and
about 200 mg per day.

The dependent claims then narrow those regimens to divided dosing and tablet administration.

100 mg daily regimen

Claims 2 through 5 cover:

100 mg daily;
tablet administration;
divided dosing; and
50 mg twice daily.

This regimen corresponds to the standard maintenance target identified in the FDA Savella labeling. The label describes titration to 50 mg twice daily, or 100 mg per day, for fibromyalgia management (FDA, 2009).

200 mg daily regimen

Claims 6 through 10 cover:

200 mg daily;
tablet administration;
divided dosing;
100 mg twice daily; and
two 50 mg tablets in the morning and two 50 mg tablets in the evening.

The 200 mg/day regimen is the labeled maximum recommended daily dose for patients who require additional treatment and can tolerate the higher exposure.

Meaning of “about”

The claims use “about 100 mg” and “about 200 mg,” rather than exact numerical amounts. The scope may therefore include clinically equivalent dosing within a reasonable range around those values. The exact range is not established solely by the claim language. Courts would consider the specification, prosecution history, technical meaning, and evidence concerning dose equivalence.

A generic product labeled for 50 mg twice daily would present a stronger historical infringement risk than a product labeled solely for an unrelated condition. A product containing milnacipran but carrying a non-fibromyalgia label would raise a different analysis under induced-infringement law.

Is the patent a formulation patent or a method-of-use patent?

US 7,888,342 is principally a method-of-use patent.

The tablet limitations in claims 3 and 7, and the detailed tablet schedule in claim 10, do not create a conventional formulation patent. The claims do not recite:

a particular excipient;
a dissolution profile;
a release mechanism;
a coating;
a particle size;
a polymorph;
a manufacturing process; or
a pharmaceutical composition defined by ingredients and proportions.

The tablet language limits how the method is practiced. It does not independently protect the tablet as a composition against all uses.

Formulation and manufacturing barriers

The patent does not appear, from the supplied claims, to create a major manufacturing barrier. A manufacturer could potentially avoid the narrow tablet claims by using another dosage form, but that strategy would not necessarily avoid claim 1 or claims 2 and 6 if the product is used to treat fibromyalgia at the claimed doses.

A separate formulation patent could change that analysis. Such a patent would need to be identified independently through the FDA Orange Book, USPTO records, and the relevant patent family. The claims supplied here do not establish protection for extended-release milnacipran, orally disintegrating tablets, capsules, liquid formulations, or manufacturing processes.

What is the FDA and Orange Book status?

Savella, containing milnacipran hydrochloride, received FDA approval for the management of fibromyalgia in January 2009. The reference product was associated with Forest Laboratories and Cypress Bioscience. The approved dosing instructions include titration to 50 mg twice daily and a maximum recommended dose of 100 mg twice daily (FDA, 2009).

The Orange Book historically listed US 7,888,342 in connection with the Savella product and fibromyalgia method-of-use protection. A method-of-use listing does not block every ANDA. It requires an applicant to address the listed patent through one of the statutory certification mechanisms.

Regulatory item	Status or significance
Reference product	Savella
Active ingredient	Milnacipran hydrochloride
FDA indication	Management of fibromyalgia
Approval date	January 2009
NDA holder history	Forest Laboratories and Cypress Bioscience
Listed patent type	Method of use
Key FDA regimen	50 mg twice daily
Maximum labeled regimen	100 mg twice daily
Regulatory pathway for generics	ANDA, with patent certification
Biosimilar pathway	Not applicable

Orange Book status can change through delisting, expiration, correction, or FDA database updates. The live FDA Orange Book entry controls the current regulatory listing, while the USPTO record controls patent status and term.

When did US Patent 7,888,342 expire?

The patent’s priority history indicates a December 2003 priority date. For a patent subject to the modern 20-year patent term, the nominal term would generally run approximately 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and applicable statutory rules.

The practical conclusion is that the patent’s nominal term fell in the 2023-2024 period, not in the late 2020s. Any pediatric exclusivity or patent-term adjustment would need to be verified in the USPTO and FDA records before using a precise expiration date in a transaction or litigation position.

As of 2025, US 7,888,342 should not be treated as an active long-dated barrier without a current USPTO term calculation. If the patent has expired, claims 1 through 10 no longer create an enforceable US exclusivity right, although the historical Orange Book listing remains relevant to prior ANDA certifications, litigation records, and generic launch chronology.

What Paragraph IV risks applied to milnacipran generics?

An ANDA applicant seeking approval for milnacipran tablets could have faced a Paragraph IV certification if US 7,888,342 was listed for the reference product when the ANDA was filed. The applicant would have asserted that the patent was invalid, unenforceable, or not infringed.

A Paragraph IV certification could trigger:

notice to the patent holder and NDA holder;
a 45-day period for filing an infringement action;
a potential 30-month FDA approval stay;
litigation over method-of-use infringement; and
possible 180-day first-applicant exclusivity if statutory requirements were met.

The commercial risk would have depended heavily on the proposed labeling. A generic applicant seeking the fibromyalgia indication would face a direct method-of-use issue. A product approved with a permissible “skinny label” omitting the patented indication could reduce inducement risk, but the analysis would depend on the final labeling, promotional conduct, prescribing patterns, and remaining patent rights.

The patent’s narrow claim focus also creates design-around options. A generic applicant could challenge claim construction around “about” dosage language, dispute the scope of “consisting essentially of,” contest validity based on anticipation or obviousness, or rely on a label that omits the patented use if legally supportable.

Which companies challenged or competed against the Savella patent estate?

The relevant competitive field has included:

generic manufacturers seeking ANDA approval for milnacipran tablets;
Forest Laboratories and its successors as reference-product commercial interests;
Cypress Bioscience as an originating commercial and patent stakeholder; and
manufacturers of competing fibromyalgia therapies, including duloxetine and pregabalin products.

The supplied claim set alone does not establish a particular Paragraph IV lawsuit, settlement, or launch agreement. A definitive litigation table requires a match to PACER complaints, FDA Paragraph IV notices, district court docket entries, and the Orange Book listing history. No specific settlement terms, royalty arrangement, or authorized-generic agreement should be inferred from the patent claims.

How strong is the patent estate?

The patent is strong against a narrow fact pattern and weak as a broad barrier to milnacipran competition.

Strengths

It covers the approved fibromyalgia indication.
It expressly covers the commercially important 50 mg twice-daily regimen.
It includes both 100 mg/day and 200 mg/day dosing.
It has dependent claims directed to tablet administration.
It was aligned with the reference product’s FDA labeling.

Weaknesses

It does not claim milnacipran as a molecule.
It does not cover all indications for milnacipran.
It does not establish composition, formulation, or manufacturing protection.
It depends on the presence of a fibromyalgia treatment use.
The “about” limitations may invite claim-construction disputes.
Its patent term has reached or passed the end of the ordinary statutory period.

The estate therefore had high historical relevance to Savella’s branded fibromyalgia market but limited residual value after patent expiration.

How does Savella patent protection compare with competing fibromyalgia drugs?

Product	Active ingredient	Main protection type	Fibromyalgia role
Savella	Milnacipran	Method of use, including dose regimen	FDA-approved fibromyalgia treatment
Cymbalta	Duloxetine	Compound, formulation, and method patents across its lifecycle	FDA-approved fibromyalgia treatment
Lyrica	Pregabalin	Compound and method patents across its lifecycle	FDA-approved fibromyalgia treatment
Generic milnacipran	Milnacipran	Typically dependent on remaining listed patents and regulatory exclusivity	Competes after relevant barriers lapse

Savella’s principal patent value was narrower than a composition-of-matter patent for duloxetine or pregabalin. Once the relevant method-of-use patent expired, the remaining barriers were more likely to involve regulatory approval, manufacturing capability, commercial scale, and market access than exclusion from the active ingredient itself.

What generic launch scenarios exist?

Three launch scenarios were commercially relevant:

Full-label launch. A generic applicant obtains approval for fibromyalgia and markets the same core indication after patent expiry or successful Paragraph IV litigation.
Skinny-label launch. The applicant omits the patented fibromyalgia indication if the regulatory and infringement analysis supports that approach.
Post-expiration launch. The applicant waits until the patent and any associated regulatory exclusivity expire, reducing litigation risk but potentially sacrificing first-mover advantages.

For a current market assessment, the principal issue is no longer whether claim 5 or claim 9 covers 50 mg twice daily. The key issue is whether any enforceable patent, regulatory exclusivity, settlement restriction, or separate formulation right remains in force.

What is the geographic coverage?

US 7,888,342 provides protection only in the United States. It does not establish rights in:

Europe;
Canada;
Japan;
Australia;
China; or
other jurisdictions.

Foreign counterparts must be reviewed separately by patent family and national phase. Expiration dates, prosecution history, claim scope, and enforcement outcomes may differ materially by country.

Key Takeaways

US 7,888,342 is a US method-of-use patent for treating fibromyalgia with milnacipran.
Claim 1 is the broadest treatment claim, while claims 2 and 6 target approximately 100 mg/day and 200 mg/day.
Claims 5 and 9 directly cover the commercially important 50 mg twice-daily and 100 mg twice-daily regimens.
The patent does not claim milnacipran itself, a specific chemical salt, a novel formulation, or a manufacturing process.
The tablet claims are method limitations, not broad composition claims.
Savella was FDA-approved in January 2009 for fibromyalgia, with a labeled target dose of 50 mg twice daily.
The patent’s ordinary term reached the 2023-2024 period, subject to USPTO term adjustment and any other statutory extension.
Biosimilar analysis does not apply because milnacipran is a small-molecule drug.
Generic risk historically centered on Paragraph IV certification, skinny-label strategy, and method-of-use infringement.
Current commercial risk depends on live USPTO and FDA records, any separate formulation patents, and the status of generic approvals.

Frequently Asked Questions

Does US Patent 7,888,342 cover all milnacipran products?

No. It covers specified methods of treating fibromyalgia with milnacipran or a pharmaceutically acceptable salt. It does not broadly cover milnacipran for every disease or every dosage form.

Does taking milnacipran at 50 mg twice daily fall within the patent claims?

Yes, that regimen is expressly recited in claim 5, subject to the patent’s validity, enforceability, and expiration status.

Is milnacipran a biologic requiring biosimilar approval?

No. Milnacipran is a small-molecule drug. Generic versions proceed through the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.

Does the patent protect extended-release milnacipran?

Not based on the supplied claims. The claims recite tablets in certain dependent claims but do not define an extended-release mechanism or other formulation technology.

Can a generic company launch milnacipran for another indication?

Potentially, subject to other patents, labeling restrictions, regulatory requirements, and inducement analysis. US 7,888,342 is limited to fibromyalgia treatment.

References

U.S. Food and Drug Administration. (2009). Savella (milnacipran hydrochloride) prescribing information. FDA.
U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,888,342, methods of treating fibromyalgia. USPTO.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Approved drug product with therapeutic equivalence evaluations, patent and exclusivity information. FDA.
U.S. Code, Title 35, §§ 154, 156, 271, and 282. Patents and patent infringement provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	552856	⤷ Start Trial
Australia	2003268020	⤷ Start Trial
Canada	2467356	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,888,342

Summary for Patent: 7,888,342